Key facts
- This page summarizes Anne Lesage's Form 3 filing for Pharvaris N.V. (PHVS).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 14:23.
Anne Lesage - 18 Mar 2026 Form 3 Insider Report for Pharvaris N.V. (PHVS)
- Reporting relationship
- Chief Early Development
- Issuer ticker
- PHVS
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 18 Mar 2026, 14:23:30 UTC
- Next SEC filing
- 24 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marnus Nel, Attorney-in-Fact for Anne Lesage
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Anne Lesage filed Form 3 for Pharvaris N.V. (PHVS) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001973705
Primary reporting owner
Lesage Anne
- Relationship
- Chief Early Development
- Address
- 1 CRANBERRY HILL SUITE 400, LEXINGTON
- Signature
- /s/ Marnus Nel, Attorney-in-Fact for Anne Lesage
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 56,450
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
PHVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 163,969
- Date
- 18 Mar 2026
- Ownership
- GRAYMATTERS CONSULTING BVBA
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $28.00
- Footnotes
- F3
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $16.05
- Footnotes
- F4
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $22.31
- Footnotes
- F5
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $8.05
- Footnotes
- F6
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,000
- Exercise price
- $18.14
- Footnotes
- F7
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $20.00
- Footnotes
- F8
PHVS
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,472
- Exercise price
- $2.59
- Footnotes
- F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -8,568 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.
Footnote F2
GrayMatters Consulting B.V., an entity controlled by Dr. Lesage.
Footnote F3
25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F4
25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F5
25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F6
25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F7
25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F8
25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F9
25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.